Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA encoding superoxide dismutase 3 + mRNA encoding I kappa B alpha super-repressor
- Development stage
- Preclinical
- Lead developer
- Factor Bioscience
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation
01
Overview
Factor Bioscience is developing a combination mRNA therapeutic consisting of mRNAs encoding the immunomodulatory proteins IκBα super-repressor (IκBα-SR) and extracellular superoxide dismutase 3 (SOD3). This therapy is designed to treat pneumonia-associated lung inflammation and Acute Respiratory Distress Syndrome (ARDS). The mechanism involves inhibiting the NF-κB pathway via IκBα-SR and reducing oxidative stress via SOD3. The mRNAs are complexed with cationic lipids and delivered via a vibrating mesh nebulizer as an aerosolized formulation to the lungs, allowing for rapid protein expression and observable amelioration of pneumonia symptoms in preclinical models.
- Other names
- mRNA encoding IκBα-SR and SOD3nebulized mRNA therapeutics for ARDSmRNA encoding I kappa B alpha super-repressor and superoxide dismutase 3
02
Targets
NF-κB
Beyond the preview
Go deeper on mRNA encoding superoxide dismutase 3 + mRNA encoding I kappa B alpha super-repressor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA encoding superoxide dismutase 3 + mRNA encoding I kappa B alpha super-repressor.